Trials / Withdrawn
WithdrawnNCT00423163
A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis
A Double-Blind, Randomized Controlled Trial of Voriconazole (VFEND®) Plus Micafungin (MYCAMINE™) Versus Voriconazole Plus Placebo in the Treatment of Patients With Proven or Probable Invasive Aspergillosis
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the therapeutic effectiveness of voriconazole + micafungin versus voriconazole alone as primary therapy for invasive aspergillosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | micafungin | |
| DRUG | voriconazole |
Timeline
- Start date
- 2007-02-01
- First posted
- 2007-01-18
- Last updated
- 2015-09-02
Locations
44 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00423163. Inclusion in this directory is not an endorsement.